Clinical Trial Update: Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

View source ↗

Summary

Long-term follow-up study of an investigational AAVAnc80-antiVEGF gene therapy for vestibular schwannoma is underway. Enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vestibular Schwannoma

Drugs mentioned

• AAVAnc80-antiVEGF gene therapy

Snippet

Sponsor: Akouos, Inc. | Conditions: Vestibular Schwannoma | Status: ENROLLING_BY_INVITATION